ArticleBrachytherapy

Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost.

Marisa A Kollmeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.